May 6 (Reuters) - Australian biotech firm CSL Ltd (CSL) said on Wednesday it will start local development of an immunoglobulin product to treat serious cases of COVID-19, the disease caused by the novel coronavirus.
The company's unit CSL Behring will develop the immunoglobulin product at its Melbourne-based Broadmeadows facility using antibodies from plasma collected from people who have recovered from COVID-19, CSL said in a statement on its website.
CSL expects around 800 plasma donations will be needed to produce enough immunoglobulin to treat around 50-100 seriously ill people under the clinical trial, it said.
May 6 (Reuters) - Australian biotech firm CSL Ltd (CSL) said on...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$299.94 |
Change
2.440(0.82%) |
Mkt cap ! $144.9B | |||
| Open | High | Low | Value | Volume |
| $297.75 | $300.00 | $297.02 | $91.43M | 312.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 56 | $299.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $299.94 | 62 | 6 |
View Market Depth
| Last trade - 13.46pm 05/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |